STERLINBIO

Sterling Biotech Limited has submitted to the Exchange a copy of voting results of Annual General Meeting of the Company held on June 30, 2015, pursuant to Clause 35A of the Listing Agreement.

Sterling Biotech Limited has informed the Exchange regarding the proceeding at the Annual General Meeting of the Company held on June 30, 2015.

Sterling Biotech Limited has informed the Exchange that the Board of Directors of the Company has approved and adopted revised code of conduct to regulate, monitor and report Insider Trading and Code of Fair Disclosure as per terms of SEBI (Prohibition of Insider Trading) Regulations.

Sterling Biotech Limited has informed the Exchange that the Annual General Meeting for the financial year ended on December 31, 2014 will be held on June 30, 2015. Further the Register of Members and Share Transfer Books of the Company shall remain closed from June 23, 2015 to June 30, 2015 (both days inclusive) for the purpose of ensuing Annual General Meeting.

Sterling Biotech Limited, Sterling Biotech Limited has submitted to the exchange the standalone financial results along with the Limited Review Report for the period ended 31-Mar-2015.

Sterling Biotech Limited has informed the Exchange that Ms. Mayuri Patel has been appointed as Independent Director of the Company.

Sterling Biotech Limited has submitted to the exchange the standalone financial results along with the Auditors Report for the period ended 31-Dec-2014.

Sterling Biotech Limited has informed the Exchange about the sad demise of Shri N B Patel, Director of the Company.

Sterling Biotech Limited has informed the Exchange that Ms. Megha Chokshi has resigned from the post of Assistant Company Secretary cum Compliance Officer w.e.f. January 3, 2015.

Sterling Biotech Limited has submitted to the exchange the standalone financial results along with the Limited Review Report for the period ended 30-Sep-2014.

Sterling Biotech Limited has submitted to the exchange the standalone financial results along with the Limited Review Report for the period ended 30-Jun-2014.

Sterling Biotech Limited has informed the Exchange regading the details of voting results of the Annual General Meeting of the shareholder of the Company held on June 30, 2014 (Clause 35A).

Sterling Biotech Limited has informed the Exchange regarding the outcome of Annual General Meeting of the members of the Company held on June 30, 2014.

Sterling Biotech Limited has informed the Exchange that the Company has fixed Book Closure from June 24, 2014 to June 30, 2014 for the purpose of Annual General Meeting to be held on June 30, 2014.

Sterling Biotech Limited has submitted to the exchange the standalone financial results for the period ended 31-Mar-2014.

JM Financial Asset Reconstruction Company Private Limited has submitted to the Exchange vide letter dated March 25, 2014 a copy of disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Sterling Biotech Limited has informed the Exchange vide letter dated March 24, 2014 regarding "Completion of Cashless Exchange Offer i.e. issue of Fresh Zero Coupon Foreign Currency Convertible Bonds due 2019 amounting to USD 206,464,000 (Fresh FCCBs) in cashless exchange of existing Zero Coupon Foreign Currency Convertible Bonds due 2012 (Existing Bonds), of which US$134,500,000 in Principal amount remained outstanding ("Cashless Exchange Offer")".

Sterling Biotech Limited has submitted to the exchange the standalone financial results for the period ended 31-Dec-2013.

Sterling Biotech Limited had informed the Exchange regarding the meeting of the Holders of the Existing Bonds scheduled to be held on November 20, 2013 for passing of extraordinary resolution to approve, amongst others, exchange and substitution of the Existing Bonds with and for the Zero Coupon Convertible Bonds due 2018 and the terms and conditions thereof. The Company has now informed the Exchange that in the meeting of the Holders of the Existing Bonds held on November 20, 2013, the Bond Holders have passed and approved, amongst others, the extraordinary resolution to approve exchange and

Sterling Biotech Limited had informed the Exchange that the meeting of the holders of Existing Bonds scheduled to be held on November 20, 2013 for passing of extraordinary resolution to approve, amongst others, exchange and substitute the Existing Bonds with and for the Zero Coupon Convertible Bonds due 2018 ( Bonds ) and the terms and conditions thereof dated on October 29, 2013. The Company has now informed the Exchange that pursuant to the resolution passed at the meeting of the Board held on November 15, 2013, the conversion price in respect of the proposed Bonds to be issued upon implemen

Sterling Biotech Limited has submitted to the exchange the standalone financial results for the period ended 30-Sep-2013.

Sterling Biotech Limited had informed the Exchange, vide letter dated May 30, 2013 regarding the extra ordinary resolution passed by holders of Zero Coupon Convertible Bonds due 2012 ("Existing Bonds") to suspend all litigations in India and UK to enable a consensual restructuring of the Existing Bonds to be agreed and implemented. The Company has now informed the Exchange that in respect of the Existing Bonds, of which US$ 134,500,000 in principal amount remain outstanding, a meeting of the Bond Holders is scheduled to be held on November 20, 2013 for passing of extraordinary resolution to ap

Sterling Biotech Limited has submitted to the Exchange the Standalone Financial Results for the period ended June 30,2013.

JM Financial Services Limited has submitted to the Exchange vide letter dated July 22, 2013 a copy of disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Sterling Biotech Limited has informed the Exchange regarding details of Voting Results under Clause 35A of Annual General Meeting held on June 29, 2013.

Sterling Biotech Limited has informed the Exchange regarding a Outcome of Annual General Meeting of the Company held on June 29, 2013.

Sterling Biotech Limited has informed the Exchange that the Annual General Meeting for the financial year ended on December 31, 2012 will be held on June 29, 2013. Further the Register of Members and Share Transfer Books of the Company shall remain closed from June 25, 2013 to June 29, 2013 (both days inclusive) for the purpose of ensuing Annual General Meeting.

Sterling Biotech Limited has informed the Exchange that in respect of the US$250,000,000 Zero Coupon Convertible Bonds (the "Bonds") Due 2012 convertible into Ordinary shares or Global Depository Receipts representing Ordinary Shares of the Company of which US$134,500,000 in principal amount remain outstanding, to enable a consensual restructuring of the Bonds to be agreed and implemented, a meeting of the Bondholders was convened by the Trustee on May 30, 2013 at Hong Kong wherein an Extraordinary Resolution was passed suspending all litigations in India and UK.

Sterling Biotech Limited has submitted to the Exchange the Standalone Financial Results along with the Limited Review Report for the period ended March 31,2013.

Sterling Biotech Limited has submitted to the Exchange the Standalone Financial Results for the period ended December 31,2012.

Sterling Biotech Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on March 01, 2013 has considered and approved the following: (1) The Board of Directors has not recommended any dividend on the equity shares for the financial year ended December 31, 2012. (2) The Board has approved the resignation of Company Secretary of the Company Shri Kirtidev Khatri with effect from February 28, 2013.

Sterling Biotech Limited has informed the Exchange that Ms. Megha R. Chokshi, an assistant company secretary of the company has been designated as compliance officer in place of Mr. Kirtidev J. Khatri.

Sterling Biotech Limited has submitted to the Exchange the Standalone Financial Results for the period ended September 30,2012 with Limited Review Report.

Sterling Biotech Limited has informed the Exchange regarding the standalone Results for the quarter ended on 30-SEP-2012 as follows: Net Sales of Rs. 19802.42 lacs for the quarter ending on 30-SEP-2012 against Rs. 22567.82 lacs and Rs. 45104.29 lacs for the quarters ending on 30-JUN-2012 and 30-SEP-2011 respectively. Net Profit / (Loss) of Rs. (7667.18) lacs for the quarter ending on 30-SEP-2012 against Rs. (8990.03) lacs and Rs. 1072.6 lacs for the quarters ending on 30-JUN-2012 and 30-SEP-2011 respectively.

Sterling Biotech Limited has submitted to the Exchange the Standalone Financial Results for the period ended June 30,2012 with Limited Review Report.

Sterling Biotech Limited has informed the Exchange vide letter dated June 30, 2012 regarding the details of voting results of the Annual General Meeting of the shareholder of the Company.

Sterling Biotech Limited has informed the Exchange regarding the Outcome of the Annual General Meeting of the Members of the Company held on June 30, 2012.

Sterling Biotech Limited has informed the Exchange that the Annual General Meeting for the financial year ended on December 31, 2011 will be held on June 30, 2012. Further the Register of Members and Share Transfer Books of the Company shall remain closed from June 26, 2012 to June 30, 2012 (both days inclusive) for the purpose of ensuing Annual General Meeting.

Sterling Biotech Limited has submitted to the Exchange the Standalone Financial Results along with the Limited Review Report for the period ended March 31,2012.

Sterling Biotech Limited has submitted to the Exchange the Standalone Financial Results for the period ended December 31,2011.

Sterling Biotech Limited has submitted to the Exchange the Standalone Financial Results for the period ended December 31,2011.

Chetan J. Sandesara has submitted to the Exchange a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Chetan J. Sandesara for and on behalf of Promoter and Promoter Group has submitted to the Exchange a copy of Disclosure under Regulation 31(1) and 31(2) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers), 2011 and amendments thereof.

Chetan J. Sandesara for and on behalf of Promoter and Promoter Group has submitted to the Exchange a copy of Regulation 31(1) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers), 2011 and amendments thereof.

Jangpriya Investments Pvt. Ltd. has submitted to the Exchange a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Sterling Biotech Limited has submitted to the Exchange the Standalone Financial Results for the period ended September 30,2011.

Sterling Biotech Limited has submitted to the Exchange a copy of the Disclosure under Regulation 8A(4) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers), 1997.

Sterling Biotech Limited has submitted to the Exchange a copy of the Disclosure under Regulation 8A(4) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers), 1997.

Sterling Biotech Limited Sterling Biotech Limited has submitted to the Exchange a copy of disclosure under Regulation 7(3) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 1997 and Regulation 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

Puja Aqua Farms Private Limited has submitted to the Exchange a copy of Disclosure under Regulation 13 of SEBI (Prohibition of Insider Trading) Regulations, 1992.